Stroke

Latest News

More Than One-Third of Stroke Survivors Have Uncontrolled Hypertension

More than one-third of stroke survivors have uncontrolled hypertension, and about one in five are not taking antihypertensive medications.

Intensive Blood Pressure Control May Improve Secondary Stroke Prevention

Intensive blood pressure lowering nonsignificantly reduces the risk for recurrence among patients with a history of stroke compared with a standard BP-lowering regimen.

Aspirin Decreases Stroke Risk in Women With Prior Hypertensive Disorders of Pregnancy

Women with a history of hypertensive disorders of pregnancy have a greater long-term risk for stroke reduced by aspirin use.

Disparities for Recurrent Hemorrhagic Stroke Risk Unexplained

Higher risk for second hemorrhagic stroke in blacks and Hispanics is not fully explained by hypertension severity.

Under New Guidelines, More Stroke Survivors With Hypertension Diagnosis

More stroke survivors are not within the new recommended blood pressure targets compared with Joint National Committee report.

Folic Acid May Cut Stroke Risk in High-Risk Hypertensive Patients

Patients with hypertension may lower their stroke risk with folic acid supplements.

Intensive Blood Pressure Lowering Provides No Mortality Benefit in Acute Intracerebral Hemorrhage

Investigators conducted a meta-analysis of trials that reported functional outcomes and mortality rates among patients with intracerebral hemorrhage following intensive blood pressure lowering.

Previous Stroke or TIA May Increase Risk for Urgency Urinary Incontinence

Independent risk factors for urgency urinary incontinence included previous stroke or transient ischemic attack, increased body mass index, and hypertension.

Pregnancy-Associated Stroke in Women With Preeclampsia

Women with preeclampsia have up to a 6-fold risk of pregnancy-associated stroke.

Lower Systolic Blood Pressure Target Did Not Improve Functional Outcomes in Intracerebral Hemorrhage

Primary treatment failure occurred in 12.2% of the intensive treatment group and only 0.8% of the standard treatment group.